Login to Your Account

Santhera, Biovail in $192M Pact for Parkinson's Drug Fipamezole

By Cormac Sheridan

Tuesday, August 25, 2009
One week after securing its ownership of the Parkinson's drug fipamezole, Santhera Pharmaceuticals Holding AG secured a partner for the compound, in the shape of Biovail Corp., which could end up paying the Swiss firm as much as $192 million in up-front, development, regulatory and commercial milestones for North American rights to the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription